Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

Johannes Gutenberg-Universität Mainz

Saarstr. 21, 55099 Mainz
  • 6131/39-0
Publikationen
Ergebnisse pro Seite:  10

Hasenburg, Annette; Blohmer, Jens-Uwe; Janni, Wolfgang et al.

Oncology - Dose-intensive training in gynecological oncology - AGO State of the Art 2023

GEBURTSHILFE UND FRAUENHEILKUNDE. Bd. 83. H. 10. 2023 S. 1179-1183


Haeuser, Friederike; Mittler, Jens; Hantal, Misra Simge et al.

One fits all: a highly sensitive combined ddPCR/pyrosequencing system for the quantification of microchimerism after hematopoietic and solid organ transplantation

CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2023


von Stein, Philipp; Besler, Christian; Riebisch, Matthias et al.

One-Year Outcomes According to Mitral Regurgitation Etiology Following Transcatheter Edge-to-Edge Repair With the PASCAL System: Results From a Multicenter Registry

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Bd. 12. H. 24. 2023



Wölfling, K; Schabinger, N

Onlinesexsucht: Patientenmerkmale und therapeutische Ansätze der sog. Onlinepornografienutzungsstörung

Deutscher Suchtkongress. Bd. 1. H. 1. 2023 S. 983



Koenig, Tatjana Tamara; Heimann, Alexander; Scharenberg, Swantje et al.

Opportunities in Differentiated School Sports Exemption - Results of An Online-Survey and Review of the Literature

KLINISCHE PADIATRIE. Bd. 235. H. 01. 2023 S. 38-44


Araki, Makoto; Park, Seung-Jung; Dauerman, Harold L. et al.

Optical coherence tomography in coronary atherosclerosis assessment and intervention (vol 19, pg 684, 2022)

NATURE REVIEWS CARDIOLOGY. 2023


Triantafyllias, Konstantinos; Marinoska, Tatjana; Heller, Caroline et al.

Optical spectral transmission to assess glucocorticoid therapy response in patients with arthritis: a longitudinal follow-up comparison with joint ultrasound

ARTHRITIS RESEARCH & THERAPY. Bd. 25. H. 1. 2023


Pfisterer, Jacobus; Joly, Florence; Kristensen, Gunnar et al.

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 4. 2023 S. 893-+